Ascendis reports Q3 2026 results as CNP therapy clears EU review, trial milestones advanceNov 12Quarterly updateAscendis Pharma A/S
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over yearAug 13Quarterly updateAscendis Pharma A/Snavepegritide